



COVID-19 Response Efforts - April 9, 2020

The State of Ohio Board of Pharmacy is committed to protecting the health and safety of Ohioans during the COVID-19 outbreak. The Board posted a document on its website that provides COVID-19 guidance and response efforts, including the issuance of waivers to assist licensees in addressing operational needs. This document will be updated regularly and can be accessed by visiting: www.pharmacy.ohio.gov/COVID. **Please be advised that a new waiver was issued today (see below).**

For more information on the state's efforts to address coronavirus, visit www.coronavirus.ohio.gov or call 1-833-4-ASK-ODH.

New COVID-19 Waiver Issued

NEW: Authorized the delegation to an Ohio-licensed APRN who is designated as a certified nurse practitioner (CNP), clinical nurse specialist (CNS), certified nurse midwife (CNM) or physician assistant (PA) the management of a consult agreement authorized under section 4729.39 of the Revised Code. This guidance can be accessed [here](#).

Clarification on Authorization for Nurses to Stock Automated Drug Storage Systems UPDATED 4/9/2020

The [authorization](#) only applies to nurses working in licensed terminal distributors of dangerous drugs that have an on-site pharmacy. Nurses that work in stand-alone facilities that do not have an on-site pharmacy (nursing homes, ambulatory surgical centers, free standing emergency departments, and clinics) have always been permitted to stock automated drug storage systems.

Clarification on Expansion of Testing Authority for COVID-19 UPDATED 4/9/2020

The Board has clarified its recent [resolution](#) authorizing testing for COVID-19. The resolution permits pharmacists, interns, and certified pharmacy technicians to conduct "FDA authorized" testing (rather than FDA approved). This includes testing that has been approved by the FDA or has been authorized under an FDA Emergency Use Authorization (EUA).

DEA Issues New Policy Permitting the Use of Unregistered Off-Site Locations to Provide Off-Site MAT Services UPDATED 4/9/2020

On April 7, 2020, the DEA issued a new [policy](#) that permits opioid treatment programs (OTPs) to use unregistered off-site locations to provide MAT services. The Board has updated its [temporary satellite registration guidance](#) to state the following:

An OTP that registers their temporary satellite location with the Board pursuant to this guidance may use unregistered off-site locations to provide MAT services in accordance with the [DEA policy](#) issued on April 7, 2020.
